Inactive Instrument

News Lexicon Pharmaceuticals, Inc. Nasdaq

Equities

US5288721047

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Lexicon: Q1 Earnings Snapshot	May. 02	AQ
Transcript : Lexicon Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, vs. Street Est of $1.4M	May. 02	MT
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update	May. 02	AQ
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target	Apr. 30	MT
Lexicon Pharmaceuticals' Chief Executive Lonnel Coats to Retire	Apr. 29	MT
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals	Apr. 29	AQ
Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Member of Its Board of Directors, Effective July 7, 2024	Apr. 29	CI
Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024	Apr. 29	CI
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024	Apr. 29	AQ
Transcript : Lexicon Pharmaceuticals, Inc. - Analyst/Investor Day	Apr. 22
Lexicon Pharmaceuticals to Host 2024 Investor Day	Apr. 18	AQ
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	AQ
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering	Mar. 25	MT
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo	Mar. 25	AQ
Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients	Mar. 12	MT
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease	Mar. 12	AQ
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease	Mar. 12	CI
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup	Mar. 11	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lexicon Pharmaceuticals, Inc. Nasdaq

Equities

US5288721047

Summary

Filters